Pfizer Tops Inaugural Pharmaceutical Emerging Markets Sales Index

Compared with other drugmakers, Pfizer generates the most sales in non-traditional markets, according to BMI's inaugural Pharmaceutical Emerging Markets Sales Index (PEMSI). The New York City-based firm recorded revenue of US$12,881mn outside of the US and Europe during 2008. However, it is important to note that this figure includes turnover from Japan, Australia and Canada, which are all universally acknowledged to be developed pharmaceutical markets.

To read the full article, please choose one of the following options: